Perpetua Resources Corp. press release
CLASS ACTION UPDATE for FCFS, MP and CABA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NASDAQ - Nasdaq Stock Market · Gold · Antimony · Silver · United States
NEW YORK, NY / ACCESSWIRE / March 7, 2022 /Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FCFS Shareholders Click Here: https://www.zlk.com/pslra-1/firstcash-inc-loss-submission-form?prid=24403&wire=1 MP Shareholders Click Here: https://www.zlk.com/pslra-1/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form?prid=24403&wire=1 CABA Shareholders Click Here: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=24403&wire=1
ADDITIONAL INFORMATION BELOW
FirstCash, Inc. (NASDAQ:FCFS)
This lawsuit is on behalf of all persons who purchased shares of FirstCash common stock between February 1, 2018 and November 12, 2021, both dates inclusive. Lead Plaintiff Deadline: March 15, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/firstcash-inc-loss-submission-form?prid=24403&wire=1
According to the filed complaint, (a) FirstCash had made more than 3,600 loans to over 1,000 active-duty members of the military and their families at usurious interest rates above 36% - and often exceeding 200% - in violation of the Military Lending Act ("MLA") and the Consent Order Cash America had entered into with the Consumer Financial Protection Bureau (the "Order"); (b) FirstCash had failed to implement the remedial measures imposed by the Order; (c) FirstCash's financial results were, in substantial part, the product of the Company's violations of the MLA and the Order; and (d) as a result of the foregoing, FirstCash was exposed to a material undisclosed risk of legal, reputational and financial harm if the Company's violations of the MLA and the Order were ever publicly disclosed.
MP Materials Corp. f/k/a Fortress Value Acquisition Corp. (NYSE:MP)
MP Lawsuit on behalf of:investors who purchased May 1, 2020 - February 2, 2022 Lead Plaintiff Deadline: April 25, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form?prid=24403&wire=1
According to the filed complaint, during the class period, MP Materials Corp. f/k/a Fortress Value Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Cabaletta Bio, Inc. (NASDAQ:CABA)
This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Cabaletta common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 24, 2019; and/or (b) Cabaletta securities between October 24, 2019 and December 13, 2021, both dates inclusive. Lead Plaintiff Deadline: April 29, 2022 TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cabaletta-bio-inc-loss-submission-form?prid=24403&wire=1
According to the filed complaint, (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta's lead product candidate, DSG3-CAART, had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff.Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Eduard Korsinsky, Esq. 55 Broadway, 10th Floor New York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500 Fax: (212) 363-7171 www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: https://www.accesswire.com/691996/CLASS-ACTION-UPDATE-for-FCFS-MP-and-CABA-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders